## Supplementary

Table S1 Association of baseline heart rate with cardiovascular events and mortality in hypertensive participants (sensitivity analysis: further adjustment for confounding factors)

| Models for outcomes ${ }^{\dagger}$ | HR (95\% CI) for categories of baseline heart rate (beats/minute) |  |  |  |  | $\mathrm{P}_{\text {trend }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | <65.5 | 65.5-71 | 71-76 | 76-82.5 | $\geq 82.5$ |  |


| Hypertensive participants |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Myocardial infarction/Total | $36 / 2,505$ | $56 / 2,674$ | $42 / 2,829$ | $54 / 3,047$ | $70 / 3,722$ | 0.315 |
| Incidence (/1,000 person-years) | 1.824 | 2.636 | 1.868 | 2.236 | 2.389 | 0.573 |
| Model 2 | $0.66(0.43,1.01)$ | ref. | $0.69(0.47,1.04)$ | $0.88(0.60,1.28)$ | $0.84(0.58,1.20)$ | 0.577 |
| Model 3 | $0.65(0.43,1.00)$ | ref. | $0.69(0.46,1.03)$ | $0.87(0.60,1.27)$ | $0.83(0.58,1.19)$ | 0.557 |
| Model 4 | $0.65(0.43,0.99)$ | ref. | $0.69(0.46,1.03)$ | $0.87(0.60,1.27)$ | $0.83(0.58,1.19)$ | $214 / 3,722$ |
| Stroke/Total | $134 / 2,505$ | $157 / 2,674$ | $158 / 2,829$ | $155 / 3,047$ | 7.386 | 0.694 |
| Incidence (/1,000 person-years) | 6.874 | 7.499 | 7.114 | 6.488 | 0.360 |  |
| Model 2 | $0.91(0.72,1.15)$ | ref. | $0.93(0.75,1.17)$ | $0.84(0.67,1.06)$ | $0.89(0.72,1.09)$ | 0.360 |
| Model 3 | $0.91(0.72,1.15)$ | ref. | $0.93(0.75,1.16)$ | $0.84(0.67,1.05)$ | $0.88(0.72,1.09)$ | 0.347 |
| Model 4 | $0.91(0.72,1.15)$ | ref. | $0.93(0.75,1.17)$ | $0.84(0.67,1.05)$ | $0.88(0.72,1.09)$ | 0.342 |
| Major cardiovascular disease /Total | $172 / 2,505$ | $216 / 2,674$ | $205 / 2,829$ | $207 / 3,047$ | $293 / 3,722$ |  |
| Incidence (/1,000 person-years) | 8.847 | 10.348 | 9.260 | 8.697 | 10.161 | 0.238 |
| Model 2 | $0.84(0.68,1.03)$ | ref. | $0.88(0.72,1.06)$ | $0.83(0.68,1.01)$ | $0.89(0.74,1.06)$ | 0.704 |
| Model 3 | $0.83(0.68,1.02)$ | ref. | $0.87(0.72,1.06)$ | $0.82(0.68,1.00)$ | $0.88(0.74,1.06)$ | 0.685 |
| Model 4 | $0.84(0.68,1.02)$ | ref. | $0.88(0.72,1.06)$ | $0.83(0.68,1.00)$ | $0.88(0.74,1.06)$ | 0.683 |
| Cardiovascular death events/Total | $33 / 2,505$ | $54 / 2,674$ | $46 / 2,829$ | $46 / 3,047$ | $85 / 3,722$ |  |
| Incidence (/1,000 person-years) | 1.667 | 2.535 | 2.040 | 1.898 | 2.891 | 0.029 |
| Model 2 | $0.62(0.40,0.96)$ | ref. | $0.79(0.53,1.18)$ | $0.78(0.52,1.18)$ | $1.04(0.73,1.48)$ | 0.077 |
| Model 3 | $0.61(0.40,0.95)$ | ref. | $0.79(0.53,1.18)$ | $0.77(0.51,1.15)$ | $1.03(0.72,1.47)$ | 0.090 |
| Model 4 | $0.61(0.39,0.95)$ | ref. | $0.79(0.53,1.18)$ | $0.76(0.51,1.14)$ | $1.02(0.72,1.45)$ | 0.101 |

${ }^{\dagger}$ Model 2 adjusted for age, sex, smoking, drinking, Body Mass Index, family history of cardiovascular disease, location, region, education, physical activity level, diastolic blood pressure, Hypercholesterolemia and center as random effect; Model 3 adjusted for age, sex, smoking, drinking, Body Mass Index, family history of cardiovascular disease, location, region, education, physical activity level, diastolic blood pressure, Hypercholesterolemia, use of beta blocker, use of calcium antagonist and center as random effect; Model 4 adjusted for age, sex, smoking, drinking, Body Mass Index, family history of cardiovascular disease, location, region, education, physical activity level, diastolic blood pressure, Hypercholesterolemia, use of beta blocker, use of calcium antagonist, use of angiotensin converting enzyme inhibitors, use of angiotensin receptor blocker, use of other types of antihypertensive drugs and center as random effect.

